Topics

Latest "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis" News Stories

03:33 EDT 30th March 2020 | BioPortfolio

Here are the most relevant search results for "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis" found in our extensive news archives from over 250 global news sources.

More Information about A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis for you to read. Along with our medical data and news we also list A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Clinical Trials, which are updated daily. BioPortfolio also has a large database of A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Companies for you to search.

Showing "Study INCB050465 Combination With Ruxolitinib Subjects With Myelofibrosis" News Articles 1–25 of 25,000+

Monday 30th March 2020

Polyphor announces positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III FORTRESS study without modifications

Polyphor AG / Key word(s): Study 30-March-2020 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, March 30, 2020 Polyphor announces positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III FORTRESS study without modifications Polyphor AG (SIX...


Benefits of bempedoic acid in hypercholesterolaemia further demonstrated by data presented at the American College of Cardiology’s 69th Annual Scientific Sessions Together with World Congress of Cardiology (ACC.20/WCC)

Bempedoic acid is being developed as a first-in-class, affordable, oral treatment which lowers low-density lipoprotein cholesterol (LDL-C), and which can be combined with other oral treatments to help lower cholesterol even further1,2,3,4,5 Data from Phase 2 study show a 40% reduction in LDL-C for patients with type 2 diabetes who are at high risk of cardiovascular events6 Two pooled analyse...

Sunday 29th March 2020

An experimental drug from Merck and Bayer cut hospitalizations for heart failure by 10% in a study published in the New England Journal of Medicine and presented virtually by the American College of Cardiology. https://buff.ly/3autAXB 

An experimental drug from Merck and Bayer cut hospitalizations for heart failure by 10% in a study published in the New England Journal of Medicine and presented virtually by the American College of Cardiology. https://buff.ly/3autAXB 


Moderna Provides Update on the Impact of COVID-19 on Business Operations and Clinical Program Development

Conference call to be held on Monday, March 30 at 8:00 a.m. ET Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today provided an update on the impact of the rapidly evolving COVID-19 pandemic on its business operations and clinical program developmen...

Increases in self-reported mental health issues, service use in Ontario

(Canadian Medical Association Journal) The number of people diagnosed with psychiatric disorders in Ontario remained stable between 2002 and 2014, but the number of people self-reporting mental health issues and using mental health services has increased, according to a study in CMAJ (Canadian Medical Association Journal).

Microbiome could help assess precancer risk in HPV patients

Gardnerella bacteria in the cervicovaginal microbiome may serve as a biomarker to identify women infected with human papillomavirus (HPV) who are at risk for progression to precancer, according to a study led by the Albert Einstein College of Medicine. Writing in the journal PLOS Pathogens, the study authors said their findings could lead to therapeutic strategies that manipulate the microbiome to...

Teeth record past stresses in life, study finds

Teeth can do more than just masticate. A new study has found that the teeth serve as one's archive in life, recording biological events, from tooth formation to death.

Gene that could affect the progress of ALS discovered

Researchers from the Zuckerman Institute at Columbia University have successfully found a gene that could work towards accelerating the progression of ALS or amyotrophic lateral sclerosis. The study titled, "The loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice," was published in the latest issue of the journal Neuron.

COVID-19 and its effects on the cardiovascular system

Researcher have reviewed the evidence showing the effects of the SARS-CoV-2 or novel coronavirus infection (COVID-19) on the cardiovascular system. Their study titled, “Potential Effects of Coronaviruses on the Cardiovascular System: A Review,” was published in the latest issue of JAMA Cardiology.

Cannabis Compound CBD Acts as Helper to Boost Antibiotic Effectiveness, Study Shows: http://ow.ly/nDIJ50yWlC3 pic.twitter.com/7m1XFo7PYJ

Cannabis Compound CBD Acts as Helper to Boost Antibiotic Effectiveness, Study Shows: http://ow.ly/nDIJ50yWlC3  pic.twitter.com/7m1XFo7PYJ

Bayer, Merck & Co. detail positive Phase III study data for vericiguat in heart failure https://www.firstwordpharma.com/node/1711471  $BAY $MRK #ACC20

Bayer, Merck & Co. detail positive Phase III study data for vericiguat in heart failure https://www.firstwordpharma.com/node/1711471  $BAY $MRK #ACC20

Study: Low Risk Of COVID-19 Transmission Via Tears, Eyewear Is Still Important

A new study, published in the Ophthalmology journal, found no traces of SARS-CoV-2 in 64 tear samples from 17 COVID-19 patients, pointing to a low risk of the coronavirus spreading through tears.

Recovery From Mild Brain Trauma Takes Longer Than Expected: Study

SUNDAY, March 29, 2020 -- Less than half of patients with a sports-related mild traumatic brain injury (mTBI) recover within two weeks, new research shows. "This study challenges current perceptions that most people with a sports-related mTBI...

Saturday 28th March 2020

Phase I/II Study Shows Promise for Melflufen in Multiple Myeloma

Researchers indicated that these results show the feasibility of this regimen and support the development of additional studies of melflufen in multiple myeloma, both in combination with dexamethasone as well as in triplet regimens.

Psychiatric disorders after first birth reduce likelihood of subsequent children

(European Society of Human Reproduction and Embryology) Women who suffer from psychiatric disorders such as depression, anxiety, mania and schizophrenia following the live birth of their first child are less likely to go on to have more children, according to the first study to investigate this in a large nationwide population. It is published in Human Reproduction.

An experimental drug from Merck and Bayer cut hospitalizations for heart failure by 10% in a new study. https://buff.ly/33QNMAt 

An experimental drug from Merck and Bayer cut hospitalizations for heart failure by 10% in a new study. https://buff.ly/33QNMAt 

STAT Plus: New drug from Merck, Bayer reduces hospitalizations for heart failure patients

An experimental drug from Merck and Bayer cut hospitalizations for heart failure by 10% in a new study.

#COVID19 Reinfection Not a Concern, Monkey Study Suggests: http://ow.ly/uT5M50yT9Jd pic.twitter.com/pWRrKOXVeu

#COVID19 Reinfection Not a Concern, Monkey Study Suggests: http://ow.ly/uT5M50yT9Jd  pic.twitter.com/pWRrKOXVeu

A study published in Nature demonstrates a device concept that exploits nanoplasmas to enable electronic devices to switch at speeds 10-100 times faster than conventional field-effect transistors. https://go.nature.com/2UH9F0F pic.twitter.com/UIKYwvIrkW

A study published in Nature demonstrates a device concept that exploits nanoplasmas to enable electronic devices to switch at speeds 10-100 times faster than conventional field-effect transistors. https://go.nature.com/2UH9F0F  pic.twitter.com/UIKYwvIrkW

Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies

Phase 3 VICTORIA Trial is the First Contemporary Outcomes Study Focused Exclusively on a Chronic Heart Failure Patient Population Following a Worsening Event Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating the efficacy and safety of its investigational drug vericiguat, an orally ...

Cardiac Injury with COVID-19 in Wuhan

According to a limited retrospective study, cardiac injury is associated with the infection and linked to higher mortality.

Increase Your Daily Step Count During Coronavirus Pandemic

Step up: As millions of people around the world heed the call to stay at home to prevent the spread of coronavirus, they can protect their long-term health by walking more. The more steps taken per day, the lower the risk of death, according to a new study.

Friday 27th March 2020

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

[Corrections] Correction to Lancet Infect Dis 2020; published online March 23. https://doi.org/10.1016/S1473-3099(20)30162

Koo JR, Cook AR, Park M, et al. Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. Lancet Infect Dis 2020; published online March 23. https://doi.org/10.1016/S1473-3099(20)30162-6—In this Article, in the sixth paragraph of the discussion, the fifth sentence should read “Even at a low infectivity (R0 ≤1·5), a high asymptomatic proportion is problematic, wit...

4840-Person Study: 12,000 Steps/Day May Reduce Death Risk Almost 16X

Can wearing a fitness tracker really save your life? Very likely ...


Quick Search

News Quicklinks